Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Rhea-AI Summary
Medicus Pharma (NASDAQ:MDCX) submitted a substantial modification application via the EU Clinical Trials Information System to support a planned Phase 2b study of Teverelix® in advanced prostate cancer patients with elevated cardiovascular risk.
The study, expected to start enrollment in 2026 subject to regulatory authorization, aims to optimize dosing and further characterize pharmacokinetics, pharmacodynamics, efficacy and safety ahead of potential registrational development for an estimated ~$4 billion annual market segment.
AI-generated analysis. Not financial advice.
Positive
- EU CTIS substantial modification filed for Teverelix Phase 2b in APC
- Targets high cardiovascular-risk APC segment with ~$4 billion annual market
- Phase 2b designed to optimize dose and characterize safety and efficacy
- Data expected to inform registrational study design in EU and US
- Teverelix described as long-acting GnRH antagonist with flare-free testosterone suppression
- Company pursuing strategy to position Teverelix for high cardiovascular-risk prostate cancer
Negative
- None.
News Market Reaction – MDCX
On the day this news was published, MDCX declined 3.14%, reflecting a moderate negative market reaction. Argus tracked a trough of -11.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $643K from the company's valuation, bringing the market cap to $19.83M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MDCX was down 6.32% while scanner peers showed mixed moves (e.g., TLPH up 5.65%, GELS down 5.29%). With no same-day peer news and directions mixed, the move appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Clinical program update | Positive | +7.0% | SkinJect® advanced to Phase 2b registrational study for Gorlin Syndrome. |
| May 28 | Financing announcement | Positive | +6.7% | Announced up to $22 million non-dilutive structured financing facility. |
| May 14 | Earnings and update | Negative | -10.7% | Q1 loss with going-concern doubt and reliance on ATM/SEPA funding. |
| May 06 | Clinical trial data | Positive | +20.9% | Positive dose-dependent Phase 2 SkinJect® results in basal cell carcinoma. |
| Apr 27 | Policy engagement | Positive | -5.7% | CEO met lawmakers seeking support for SkinJect® orphan and voucher paths. |
News flow has generally aligned with price reactions, with positive clinical and financing updates preceding gains, while more mixed or political headlines have not always been rewarded.
Over the past few months, Medicus has issued several clinically and strategically important updates. Positive Phase 2 SkinJect® data and a Gorlin Syndrome registrational plan on May 14 and June 3 were followed by double-digit and mid-single-digit gains. A $22 million non-dilutive financing on May 28 also coincided with a gain. In contrast, earnings highlighting going-concern risk and a policy-focused Capitol Hill visit on May 14 and April 27 saw negative reactions. Today’s Teverelix® advancement extends this pattern of clinically focused milestones.
Market Pulse Summary
This announcement advances Teverelix® toward a Phase 2b study targeting advanced prostate cancer patients with elevated cardiovascular risk, a population estimated at an annual opportunity of roughly $4 billion. It complements earlier SkinJect® and financing milestones, underscoring a multi-asset pipeline strategy. Investors may track upcoming regulatory clearances, Phase 2b design details, and future data readouts alongside existing balance-sheet disclosures and Nasdaq compliance steps to gauge execution risk and value creation.
Key Terms
androgen deprivation therapy medical
phase 2b medical
european union clinical trials information system (ctis) regulatory
gnrh antagonist medical
follicle-stimulating hormone medical
depot formulation medical
new drug application regulatory
orphan drug designation regulatory
AI-generated analysis. Not financial advice.
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS) supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer (APC).
The submission represents an important milestone in Medicus’ strategy to advance Teverelix® toward registrational development focused on one of the largest unmet needs in prostate cancer treatment: patients with elevated cardiovascular risk requiring androgen deprivation therapy (ADT).
“Cardiovascular disease remains one of the most significant challenges facing men undergoing androgen deprivation therapy,” stated Dr. Raza Bokhari, Medicus’ Executive Chairman & CEO, “We believe Teverelix’s® unique pharmacologic profile, including flare-free rapid testosterone suppression, profound follicle-stimulating hormone suppression and a long-acting depot formulation, may offer meaningful advantages for this patient population. This study is intended to generate the data necessary to support registrational planning and advance discussions with regulatory authorities in Europe and the United States.”
The planned Phase 2b study is designed to optimize dose selection and further characterize the pharmacokinetic, pharmacodynamic, efficacy and safety profile of Teverelix® ahead of planned registrational development. Medicus has previously engaged extensively with the U.S. Food and Drug Administration regarding its APC development strategy, including future studies focused on patients with elevated cardiovascular risk.
Teverelix®: Differentiated Mechanism with Cardiovascular Relevance
Teverelix® is a long-acting GnRH antagonist designed to provide rapid, flare-free testosterone suppression together with profound follicle-stimulating hormone (FSH) suppression through a convenient depot formulation. The Company believes these characteristics may provide meaningful differentiation from traditional GnRH agonists and support evaluation in patients where cardiovascular outcomes are of particular importance.
Advanced prostate cancer remains one of the largest oncology markets worldwide, with ADT serving as the backbone of treatment for hundreds of thousands of patients annually. Cardiovascular disease is increasingly recognized as a leading cause of mortality among men with advanced prostate cancer, with published studies suggesting that approximately
While currently approved GnRH antagonists have demonstrated encouraging cardiovascular findings in clinical studies, no hormonal therapy has been specifically developed or prospectively positioned for patients with elevated cardiovascular risk. Medicus believes Teverelix® may provide an opportunity to address this important unmet need through a dedicated development strategy focused on this patient population.
The Company estimates that advanced prostate cancer patients with elevated cardiovascular risk represent an approximately
Subject to regulatory review and authorization, Medicus intends to initiate patient enrollment later this year. Data generated from the Phase 2b study are expected to inform dose selection, registrational study design and future regulatory interactions in both Europe and the United States.
Medicus’ goal is to establish Teverelix® as the best-in-class hormonal therapy prospectively developed for advanced prostate cancer patients where cardiovascular risk is a major treatment consideration.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.
The Company’s current key therapeutics assets are:
SkinJect®, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing a ~
Teverelix®, a next-generation GnRH antagonist, is a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing a ~
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the collaboration with Gorlin Syndrome Alliance (GSA) including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect®), ability to be approved for the Registrational IND Program to enable those suffering with Gorlin Syndrome to access SkinJect® under physician-supervised treatment protocols, the submission of Protocol SKNJCT-005 and the design, timing, conduct and results of the SKNJCT-005 Phase 2b registrational study, including whether the resulting data will be sufficient to support a future New Drug Application for SkinJect® in Gorlin Syndrome, the potential for SkinJect® to become the first FDA-approved lesion-directed therapy for patients with Gorlin Syndrome and a new standard of care for this patient population; and the Company's intention to apply for a Rare Pediatric Disease Priority Review Voucher and the potential issuance and benefits of such voucher, Orphan drug designation for SkinJect®, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer, women’s health indications like endometriosis, and the potential market opportunities related thereto, the memorandum of understanding with HelixNano, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company’s submission for approval in the FDA Commissioner's National Priority Voucher program plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect® through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company’s expectations regarding reported efficacy findings, the overall response rate and potential changes thereto, and whether there will be material changes to its reported SKNJCT-003 topline results and to secure an EOP2 meeting with the FDA in the second half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", “on track”, “aim”, "might", "will", "will likely result", “could,” “designed,” "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2025, and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
